Abstract:Oral administration of nanocarriers remains a significant challenge in the pharmaceutical sciences. The nanocarriers must efficiently overcome multiple gastrointestinal barriers including the harsh gastrointestinal environment, the mucosal layer, and the epithelium. Neutral hydrophilic surfaces are reportedly necessary for mucus permeation, but hydrophobic and cationic surfaces are important for efficient epithelial absorption. To accommodate these conflicting surface property requirements, we developed a strategy to modify nanocarrier surfaces with cationic cell-penetrating peptides (CPP) concealed by a hydrophilic succinylated casein (SCN) layer. SCN is a mucus-inert natural material specifically degraded in the intestine, thus protecting nanocarriers from the harsh gastric environment, facilitating their mucus permeation, and inducing exposure of CPPs after degradation for further effective transepithelial transport. Quantum dots doped hollow silica nanoparticles (HSQN) with a diameter around 180 nm was used as the nanocarrier and demonstrated as high as 50% loading efficacy of paclitaxel, a model drug with poor solubility and permeability. The dual layer modification strategy prevented premature drug leakage in stomach and maintained high mucus permeation (the trajectory spanned 9-fold larger area than single CPP modification). After intestinal degradation of SCN by trypsin, these nanocarriers exhibited strong interaction with epithelial membranes and a 5-fold increase in cellular uptake. Significant transepithelial transport and intestinal distribution were also observed for this dual-modified formulation. A pharmacokinetics study on the paclitaxel-loaded nanocarrier found 40% absolute bioavailability and 7.8-fold higher AUC compared to oral Taxol®. Compared with single CPP modified nanocarriers, our formulation showed increased in vivo efficacy and tumor accumulation of the model drug with negligible intestinal toxicity. In summary, sequential modification with CPP and SCN layers on HSQN offers a potential strategy to overcome the multiple barriers of the gastrointestinal tract.

Functional Nanocarrier for Drug and Gene Delivery Via Local Administration in Mucosal Tissues

Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery

Nanoparticle-based Local Antimicrobial Drug Delivery

Advances of nanoparticles in transmucosal drug delivery

Nanoparticle-Mediated Strategies for Enhanced Drug Penetration and Retention in the Airway Mucosa

Ultrasound-Mediated Local Drug and Gene Delivery Using Nanocarriers

Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems

Advance in Nanomedicine for Improving Mucosal Penetration and Effective Therapy of Cervical Cancer

In vivo and in vitro effect of ozone and formaldehyde on human nasal mucociliary transport system.

Advances in surface-modified nanometal-organic frameworks for drug delivery

Nanocarriers transport across the gastrointestinal barriers: The contribution to oral bioavailability via blood circulation and lymphatic pathway

Bioadhesive Nanoparticles for Local Drug Delivery

Rotation-Facilitated Rapid Transport of Nanorods in Mucosal Tissues

Overcoming Multiple Gastrointestinal Barriers by Bilayer Modified Hollow Mesoporous Silica Nanocarriers.

Mucus-Penetrating PEGylated Nanoshuttle for Enhanced Drug Delivery and Healthcare Applications

Intestinal nanoparticle delivery and cellular response: a review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties

Betaine-Based and Polyguanidine-Inserted Zwitterionic Micelle as a Promising Platform to Conquer the Intestinal Mucosal Barrier

Nanocarriers for promoting skin delivery of therapeutic agents

Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types

Peroral Targeting of Drug Micro or Nanocarriers to Sites Beyond the Gastrointestinal Tract.

Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions